GSK plc (GLAXF)
OTCMKTS · Delayed Price · Currency is USD
23.99
+1.53 (6.81%)
Nov 21, 2025, 4:00 PM EST
GSK plc Revenue
GSK plc had revenue of 8.55B GBP in the quarter ending September 30, 2025, with 6.68% growth. This brings the company's revenue in the last twelve months to 32.17B, up 2.73% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
32.17B GBP
Revenue Growth
+2.73%
P/S Ratio
2.18
Revenue / Employee
468.69K GBP
Employees
68,629
Market Cap
94.43B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| Tian'an Technology Group | 2.12M |
GSK plc News
- 3 days ago - AnaptysBio Buckles After Trading Legal Barbs With Pharma Giant GSK - Investor's Business Daily
- 3 days ago - Why GSK (GSK) is a Top Value Stock for the Long-Term - Nasdaq
- 3 days ago - AnaptysBio (ANAB) Faces Legal Battle with GSK's Subsidiary Over Cancer Drug Agreement - GuruFocus
- 3 days ago - AnaptysBio (ANAB) Shares Plunge Amid Legal Battle with GSK - GuruFocus
- 3 days ago - AnaptysBio shares tumble after legal fight with GSK over cancer drug license - Reuters
- 3 days ago - GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga
- 3 days ago - GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga
- 3 days ago - AnaptysBio drops as litigation with GSK unit risks cancer therapy deal - Seeking Alpha